MedTrace Logo

Management of Superficial Thrombophlebitis

NCT00264381 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2013-11-18

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test the hypothesis that Fragmin (dalteparin sodium) subcutaneously once daily for 7 days is more effective than Ibuprofen given orally three times daily for 7 days for the treatment of superficial thrombophlebitis (STP).

Conditions

  • Superficial Thrombophlebitis
  • Upper Extremity Superficial Thrombophlebitis
  • Lower Extremity Superficial Thrombophlebitis

Interventions

DRUG

Dalteparin sodium injection

Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Suman Rathbun, M.D. · University of Oklahoma Medicine/Cardiovascular Section

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2009-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264381 on ClinicalTrials.gov